Clinical trials
Malignancy clinical trials
Below are recruiting malignancy clinical trials, each written for real people, not researchers. We’re tracking 1,585 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05768178RecruitingPhase 2/Phase 3
Vemurafenib plus cobimetinib for BRAF-mutant cancers
This trial tests whether combining two targeted cancer medicines—vemurafenib and cobimetinib—can treat adults whose tumors have a specific “BRAF V600” mutation. You may be screened with blood tests and a tissue biopsy before starting treatment.
BelfastAges 18 years+ - NCT05779605Recruiting
Online rehab for lymphoma survivors after chemotherapy
This trial tests a telerehabilitation (remote exercise/rehab) program for people with recent lymphoma or other blood cancers after chemotherapy. It aims to improve recovery and fitness while monitoring safety through an exercise test and check-ins.
BrnoAges 18 years+ - NCT05786716RecruitingPhase 2/Phase 3
Trastuzumab plus pertuzumab for HER2-mutated cancers
This trial tests whether combining trastuzumab and pertuzumab can treat cancers that have HER2 amplification or an activating HER2 mutation. It looks at people ages 12 and older, and may include both children/teens and adults, using the study drug based on their HER2 test results.
BelfastAges 12 years+ - NCT05786924RecruitingPhase 1/Phase 2
Targeted cancer drug study for RAS/RAF mutation-positive tumors
This Phase 1/2 study tests S241656 (a targeted cancer medicine) in people whose cancers have certain “RAS/RAF” gene changes. It may help shrink tumors or control cancer growth, and also finds the safest dose and best way to use the drug.
Gilbert, ArizonaAges 18 years+ - NCT05793749Recruiting
Prevent leg swelling after gynecologic cancer treatment
This study tests an early approach to help prevent lower-limb lymphedema (chronic leg swelling) after lymph node surgery and radiotherapy for gynecologic cancer. If you’re at risk, it may help your legs stay less swollen and reduce complications.
Chongqing, Chongqing MunicipalityAges 18–60 - NCT05794880Recruiting
Immunotherapy lowering immune cells before transplant in children
This trial tests a special immune-cell “preparation” treatment (called T-cell and B-cell depletion) with adjusted anti-thymocyte globulin (ATG) dosing before a stem cell transplant. It aims to reduce immune-related transplant complications in people under 25 with certain blood cancers in a specific remission status.
Milwaukee, WisconsinAges birth–25 years - NCT05797649Recruiting
Test a pleural fluid blood marker to tell heart failure vs others
This study checks whether a substance called NT-proBNP in pleural fluid can better identify if fluid around the lung is caused by heart failure. If you fit, the results may help doctors choose faster, more accurate diagnosis for your pleural effusion.
Hong Kong, New TerritoriesAges 18 years+ - NCT05800210RecruitingPhase 2
T cell and B cell immune “wipeout” after stem cell transplant
This Phase 2 trial studies whether removing certain immune cells (alpha/beta T cells and CD19+ B cells) around the time of a stem cell transplant can improve outcomes for people with high-risk blood cancers. It may help by reducing the immune responses that can interfere with the transplant working, while keeping the process safe.
Gainesville, FloridaAges 6 months–39 years - NCT05802186Recruiting
AI-guided radiation plan for lung cancer tumors
This study uses an AI tool to help plan how doctors deliver focused radiation to lung tumors. It may help make radiation targeting more precise and support treatment safety for people with primary or limited metastatic lung cancer.
Chicago, IllinoisAges 18 years+ - NCT05807789Recruiting
Genetic testing during CAR-T treatment for adults
This study looks at a patient’s genetic (molecular) information while they receive CAR-T cell therapy. The goal is to better understand how different biological factors may affect CAR-T treatment.
Bologna, ItalyAges 18–70 - NCT05827835RecruitingPhase 1/Phase 2
CD7 CAR-T treatment then stem cell transplant for CD7 leukemia
This trial tests a new immune cell therapy (CD7 CAR-T) given as a bridge to a stem cell transplant in people with relapsed or hard-to-treat CD7-positive leukemia. The goal is to help control the leukemia and improve chances for a successful transplant.
Hangzhou, ZhejiangAges 18 years+ - NCT05830058RecruitingPhase 2
PET-guided focused radiation for limited worsening lung, melanoma, kidney cancer
This Phase 2 study tests whether using a PET scan to guide focused radiation (SBRT) can control a small number of cancer spots that are starting to grow despite prior treatment. It may help patients avoid wider radiation by targeting only the limited progressing areas.
Duarte, CaliforniaAges 18 years+ - NCT05831631Recruiting
Study immune cells in brain tumors during neurosurgery
This study looks at different immune cells in the blood and inside brain tumors. It includes adults who have a malignant brain tumor and need a neurosurgery procedure, such as surgery, stereotactic biopsy, or radiosurgery, to help doctors better understand the immune response.
Milan, MilanAges 18 years+ - NCT05836896RecruitingPhase 1
Safety check of BCMA CAR T-cells made from your own immune cells
This early-phase trial tests whether a personalized BCMA-targeting CAR T-cell treatment is safe and what dose is tolerable in people whose lymphoma or myeloma has come back or did not respond to prior treatment. If you qualify, the team will monitor you closely for side effects to find the safest maximum tolerated dose.
DresdenAges 18 years+ - NCT05847348RecruitingPhase 3
PET scan for rising PSA after prostate cancer treatment
This Phase 3 trial tests whether a special PET scan using 68Ga-PSMA-11 can detect prostate cancer that has returned after surgery or radiation, measured by rising PSA. If the scan works well, it may help doctors find where the cancer is coming back.
BeijingAges 18 years+ - NCT05849207RecruitingPhase 1
Cyclophosphamide after transplant for people 65 and older
This early-phase study tests giving cyclophosphamide after a specific type of stem cell transplant (haploidentical) in people age 65 and older. It aims to improve transplant safety and outcomes by adjusting medicine given after the graft is placed.
Los Angeles, CaliforniaAges 65 years+ - NCT05853783Recruiting
Testing a mouth test on biopsy samples from abnormal lesions
This trial looks at archived (saved) mouth biopsy samples to see how well the STRATICYTE™ test can identify potentially dangerous “pre-cancer-like” changes. It may help doctors screen or better understand which abnormal areas in the mouth later turn into oral cancer.
Birmingham, AlabamaAges 18 years+ - NCT05865301Recruiting
Outcomes after approved immunotherapy for young blood cancer patients
This study looks at the real-world results of treating certain B-cell blood cancers in children and young adults with commercially available immunotherapy. It may help doctors better understand how these treatments work for patients after relapse or when they need additional therapy.
Tucson, ArizonaAges Up to 26 years - NCT05875805Recruiting
Telehealth planning for future care decisions
This trial tests a telehealth (video or phone) program that helps people with certain blood cancers plan their future care preferences. It may help you and your chosen support person communicate your wishes clearly, especially if you become too sick to speak for yourself.
Rochester, New YorkAges 60 years+ - NCT05880043RecruitingPhase 1/Phase 2
IV NK cell treatment for advanced cancers that returned
This Phase 1/2 study tests an intravenous (IV) immune-cell therapy made from donors (allogeneic NK cells) to treat advanced solid tumors, relapsed/refractory non-Hodgkin lymphoma, or multiple myeloma. It may help by targeting cancer cells more directly, but early-phase trials mainly focus on safety and finding the right dosing.
SeoulAges 19 years+ - NCT05882175Recruiting
Checking how well an index predicts blood cancer care
This trial looks at how well a measurement called the OHI Index works for people with blood cancers. It may help doctors better assess risk or needs, but it mainly focuses on validating the tool rather than testing a new drug.
Kfar SabaAges 18 years+ - NCT05887687Recruiting
Ga-68 PET/CT scan for people with cancer
This trial looks at using a specific PET/CT scan (a whole-body imaging test) to help evaluate cancer that is confirmed or suspected. If you are eligible, you may receive this scan soon after a recent FDG PET/CT to compare or improve how cancers are identified.
Beijing, Beijing MunicipalityAges 18–75 - NCT05888532RecruitingPhase 1/Phase 2
Testing a copper-based scan and treatment in advanced cancers
This Phase 1/2 trial studies a copper-labeled medicine called 64Cu-GRIP B in people with advanced, metastatic cancers. It may help doctors see where cancer is and how well the drug works, especially alongside immune checkpoint therapy for some cancer types.
San Francisco, CaliforniaAges 18 years+ - NCT05892393RecruitingPhase 1
Scan test to find CD46-positive multiple myeloma lesions
This Phase 1 study tests a new special scan marker (a radioactive imaging agent) to see whether it can detect certain multiple myeloma spots in the body. If it works, it may help doctors better locate disease using a PET-style scan.
San Francisco, CaliforniaAges 18 years+
Hear when a new Malignancy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for malignancy?
- Yes. Clin2 currently lists 1,585 recruiting malignancy studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a malignancy trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a malignancy trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.